80 Beats Medical closes a €2.4 million financing package to advance non-invasive cardiovascular assessment for women. The package combines private seed investment with non-dilutive public funding. The financing will support further development and commercialisation of applications built on our VICORDER® platform, starting with antenatal care.
The platform uses a cuff to collect cardiovascular measurements non-invasively. We are investigating whether these measurements can help identify women at increased risk of pregnancy complications earlier and inform clinical decisions.
What the financing will support
The funding will help us prepare HERA for commercialisation. With HERA, we aim to bring non-invasive assessment of maternal haemodynamics closer to routine antenatal care.
Alongside this work, we will continue to develop and clinically validate the PERI Score. It is designed to combine cardiovascular measurements with clinical information to improve the assessment of preeclampsia risk. Our collaboration with King’s College London and King’s College Hospital NHS Foundation Trust gives us access to anonymised cardiovascular data from more than 20,000 pregnancies. These data will support further development and clinical validation of the PERI Score.
Our longer-term plans extend beyond antenatal care. We will advance our regulatory and commercial plans and lay the groundwork for further applications in cardiovascular risk assessment for women at different stages of life.
We thank our investors, public funding partners, clinical collaborators, and team for their support.
Co-funded by the European Union.
